Pioglitazone Improves Aortic Wall Elasticity in a Rat Model of Elastocalcinotic Arteriosclerosis
Specific treatment of age-related aortic wall arteriosclerosis and stiffening is lacking. Because ligands for peroxisome proliferator–activated receptor γ have beneficial effects on the arterial wall in atherosclerosis, via an antiinflammatory mechanism, we investigated whether long-term pioglitazon...
Saved in:
Published in: | Hypertension (Dallas, Tex. 1979) Vol. 46; no. 2; pp. 372 - 379 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Philadelphia, PA
American Heart Association, Inc
01-08-2005
Hagerstown, MD Lippincott |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Specific treatment of age-related aortic wall arteriosclerosis and stiffening is lacking. Because ligands for peroxisome proliferator–activated receptor γ have beneficial effects on the arterial wall in atherosclerosis, via an antiinflammatory mechanism, we investigated whether long-term pioglitazone (Pio) treatment protects against another form of vascular wall disease, arteriosclerosis. We evaluated, in a rat model of elastocalcinotic arteriosclerosis (hypervitaminosis D and nicotine [VDN]), whether Pio (3 mg · kg per day for 1.5 month PO) attenuated arteriosclerosis and its consequencesaortic wall rigidity, increased aortic pulse pressure, and left ventricular hypertrophy. In VDN rats, medial calcification was associated with monocyte/macrophage infiltration and induction of tumor necrosis factor α and interleukin 1β. Pio increased nuclear peroxisome proliferator–activated receptor γ immunostaining in the aortic wall, decreased tumor necrosis factor α (P<0.05 versus VDN Pio), tended to decrease interleukin 1β mRNA expression (P=0.08 versus VDN Pio), blunted aortic wall calcification (271±69, P<0.05 versus VDN Pio 562±87 μmol · g dry weight) and prevented fragmentation of elastic fibers (segments per 10 000 μm8.4±0.3; P<0.05 versus VDN Pio 10.5±0.6). Pio reduced aortic wall stiffness (elastic modulus/wall stress4.8±0.6; P<0.05 versus VDN Pio 10.0±1.6), aortic pulse pressure (30±2 mm Hg; P<0.05 versus VDN Pio 39±4) and left ventricular hypertrophy (1.58±0.05 g · kg; P<0.05 versus VDN Pio 1.76±0.06). In conclusion, long-term Pio treatment attenuates aortic wall elastocalcinosis and, thus, lowers aortic wall stiffness, aortic pulse pressure, and left ventricular hypertrophy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0194-911X 1524-4563 |
DOI: | 10.1161/01.HYP.0000171472.24422.33 |